Market Overview

MediciNova (NASDAQ:MNOV) Press Releases

Monday, January 21, 2019

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases (MNOV, News, Legal, Press Releases / Mon, 06:00pm)

Tuesday, January 08, 2019

MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma (MNOV, Health Care, Press Releases / Tue, 06:00pm)

Monday, January 07, 2019

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan (MNOV, News, Legal, Press Releases, General / Mon, 06:00pm)

Wednesday, December 12, 2018

MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco (MNOV, Press Releases / Wed, 06:00am)

Thursday, October 04, 2018

MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma (MNOV, Press Releases / Thu, 06:00pm)

Tuesday, September 25, 2018

MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS (MNOV, Health Care, Press Releases / Tue, 06:00pm)

Tuesday, September 18, 2018

MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York (MNOV, News, Press Releases / Tue, 06:00pm)

Tuesday, September 04, 2018

MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York (MNOV, News, Press Releases / Tue, 06:00pm)

Wednesday, August 29, 2018

MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine (MNOV, Health Care, Press Releases / Wed, 04:00pm)

Monday, August 20, 2018

Monday, August 06, 2018

MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge (MNOV, Press Releases, General / Mon, 06:00pm)

Tuesday, July 31, 2018

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK (MNOV, News, Press Releases / Tue, 06:00pm)

Sunday, July 29, 2018

MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial (MNOV, Press Releases / Sun, 06:00pm)

Wednesday, July 11, 2018

Drug Developers Expecting Significant Clinical and Economic Benefits by Targeting Newest Drug Therapies (BCRX, CELG, MBRX, MNOV, XLRN, Retail Sales, Small Cap, Opinion, Press Releases / Wed, 07:15am)

Monday, July 09, 2018

MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS (MNOV, Health Care, Press Releases / Mon, 06:00pm)

Tuesday, June 19, 2018

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan (MNOV, News, Legal, Press Releases / Tue, 06:00pm)

Tuesday, June 05, 2018

Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway — What Drives Growth in Today's Competitive Landscape (CLLS, CP, DSGX, GLPG, LOGI, MNOV, Press Releases / Tue, 06:35am)

Wednesday, May 09, 2018

MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma (MNOV, Press Releases / Wed, 06:00pm)

Tuesday, May 08, 2018

MediciNova to Present at the UBS Global Healthcare Conference in New York (MNOV, Press Releases / Tue, 06:00pm)

Monday, May 07, 2018

MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal (MNOV, Press Releases / Mon, 06:00pm)

Thursday, April 26, 2018

MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting (MNOV, Press Releases / Thu, 06:00pm)

Tuesday, April 24, 2018

MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data (MNOV, Press Releases / Tue, 05:30am)

Monday, April 23, 2018

Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer (DARE, INNV, MNOV, Press Releases / Mon, 05:00am)

Friday, April 13, 2018

MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France (MNOV, Health Care, Retail Sales, Press Releases / Fri, 05:30am)

Thursday, April 12, 2018

Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences — Renewed Outlook, Key Drivers of Growth (DERM, LAUR, LMRK, MDCA, MNOV, PZN, Press Releases / Thu, 07:20am)

Sunday, April 01, 2018

MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis (MNOV, Press Releases / Sun, 06:00pm)

Thursday, March 29, 2018

MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence (MNOV, Health Care, Press Releases / Thu, 05:30am)

Wednesday, March 28, 2018

MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy (MNOV, Press Releases / Wed, 06:00pm)

Thursday, March 15, 2018

Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and MediciNova — New Horizons, Emerging Trends, and Upcoming De (CETV, GLNG, MNOV, OMAB, RDI, RYTM, Press Releases / Thu, 07:15am)

Monday, March 12, 2018

MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo (MNOV, News, Press Releases / Mon, 06:00pm)

Sunday, February 25, 2018

MediciNova to Present at the Cowen Health Care Conference in Boston (MNOV, News, Press Releases / Sun, 06:00pm)

Sunday, February 18, 2018

MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California (MNOV, News, Press Releases / Sun, 06:00pm)

Monday, February 12, 2018

MediciNova Announces Closing of Underwritten Public Offering of Common Stock (LTS, MNOV, Markets, Press Releases / Mon, 06:30pm)

Wednesday, February 07, 2018

MediciNova Announces Pricing of Underwritten Public Offering of Common Stock (LTS, MNOV, Markets, Press Releases / Wed, 07:12pm)
MediciNova Announces Proposed Underwritten Public Offering of Common Stock (LTS, MNOV, Markets, Press Releases / Wed, 04:00pm)

1	VNDA, GLOB: 31 Stocks Moving In Friday's Pre-Market Session
2	VFFIF, MMNFF: Pot Stocks, ETFs, Top News And Data From The Cannabis Indu...
3	GOOS: Canada Goose Analysts React To Q3 Print: Should Invest...
4	STZ, CGC: Canopy Growth's Q3 Revenue Jumps 283% Yea...
5	REED, ANET: 10 Stocks To Watch For February 15, 2019
6	ACB, MJ: The Marijuana ETF Continues T...
7	TRUE, QTWO: Benzinga's Top...

1	TCEHY, EA: EA's 'Apex Legends' Could Expand To China With Tencent
2	Where Is The Best Place To Land A Job This Year?
3	Sierra Snowstorm Could Close More Roads This Weekend
4	CGC: Canopy Growth Reports Better Retail Cannabis Availability As Revenue...
5	SVVTF, CRON: Pot Stocks, ETFs, Top News And Data From The Cannabis Ind...
6	AMZN, TSLA: Analysis: Why New York's Amazon Bungle Is...
7	AMZN: Amazon Says No Thanks To NYC: What Do The E...